Haemonetics earnings were $167.7M for the trailing 12 months ending Mar 29, 2025, with 43.5% growth year over year. The latest HAE earnings report on Mar 29, 2025 announced Q1 2025 earnings of $58.0M, up 54.6% from last quarter. For the last reported fiscal year 2025 ending Mar 29, 2025, HAE reported annual earnings of $167.7M, with 42.6% growth.
HAE past earnings growth
How has HAE's earnings growth performed historically?
On HAE's earnings call on Invalid Date, Haemonetics (NYSE: HAE) reported Q1 2025 earnings per share (EPS) of $1.17, up 192.5% year over year. Total HAE earnings for the quarter were $57.98 million. In the same quarter last year, Haemonetics's earnings per share (EPS) was $0.40.
As of the last Haemonetics earnings report, Haemonetics is currently profitable. Haemonetics's net profit (also called net income) for the twelve months ending Mar 29, 2025 was $167.68 million, a 42.64% increase year over year.
What was HAE's earnings growth in the past year?
As of Haemonetics's earnings date in Invalid Date, Haemonetics's earnings has grown 43.53% year over year. This is 27.6 percentage points higher than the US Medical Instruments & Supplies industry earnings growth rate of 15.93%. HAE earnings in the past year totalled $167.68 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.